Immunome Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Immunome Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- IMNM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001472012
Board of directors
-
Carol Schafer · DirectorSince 2024
-
Clay B. Siegall · Director · President and CEOSince 2023
-
Franklyn G. Prendergast · DirectorSince 2023
-
Isaac Barchas · DirectorSince 2023
-
James P. Boylan · DirectorSince 2023
- Since 2023
-
John L. Lamattina · DirectorSince 2023
-
Michael Lefenfeld · DirectorSince 2023
-
Michael Rapp · DirectorSince 2023
-
Philip Wagenheim · DirectorSince 2023
-
Purnanand D. Sarma · Director · President and CEOSince 2023
-
Richard A. Baron · DirectorSince 2023
-
Sandra M. Swain · DirectorSince 2024
Chief executives
Clay B. Siegall
· President and CEO
Dates unknown
Purnanand D. Sarma
· President and CEO
Dates unknown
Board connections
6 of this board's directors also sit on 12 other boards.
- via Jean Jacques Bienaime
- via Jean Jacques Bienaime
- via James P. Boylan
- via James P. Boylan
- via Jean Jacques Bienaime
- via Carol Schafer
- via Jean Jacques Bienaime
- via Carol Schafer
- via John L. Lamattina
- via Clay B. Siegall
- via Philip Wagenheim
- via James P. Boylan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $2,305,990
- 11 purchases by 3 insiders
- Sold, last 12 months
- $27,508,461
- 28 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 11, 2026 | Higgins Jack Officer (Chief Scientific Officer) | Option exercise | +18,000 | $1.35 | $24,300 |
| Sep 11, 2026 | Higgins Jack Officer (Chief Scientific Officer) | Open-market sale | −13,200 | $25.32 | $334,224 |
| Sep 11, 2026 | Higgins Jack Officer (Chief Scientific Officer) | Gift | −8,800 | — | — |
| Aug 12, 2026 | Isaac Barchas Director | Open-market sale | −11,048 | $27.25 | $301,058 |
| Aug 11, 2026 | Isaac Barchas Director | Open-market sale | −62,291 | $26.23 | $1,633,893 |
| Aug 10, 2026 | Isaac Barchas Director | Open-market sale | −10,125 | $26.07 | $263,959 |
| Aug 7, 2026 | Isaac Barchas Director | Open-market sale | −15,248 | $26.06 | $397,363 |
| Aug 6, 2026 | Isaac Barchas Director | Open-market sale | −20,840 | $26.06 | $543,090 |
| Aug 4, 2026 | Horn Kinney Officer (CHIEF BUSINESS OFFICER) | Option exercise | +50,366 | $12.92 | $650,729 |
| Aug 4, 2026 | Horn Kinney Officer (CHIEF BUSINESS OFFICER) | Option exercise | +40,250 | $10.60 | $426,650 |
| Aug 4, 2026 | Horn Kinney Officer (CHIEF BUSINESS OFFICER) | Open-market sale | −90,616 | $25.09 | $2,273,555 |
| Jul 23, 2026 | Higgins Jack Officer (Chief Scientific Officer) | Grant or award | +38,250 | — | — |
| Jul 23, 2026 | Horn Kinney Officer (CHIEF BUSINESS OFFICER) | Grant or award | +31,250 | — | — |
| Jul 23, 2026 | Clay B. Siegall Director, Officer (President and CEO) | Grant or award | +180,000 | — | — |
| Jul 23, 2026 | Stoneman Sandra G. Officer (CHIEF LEGAL OFFICER & GC) | Grant or award | +38,250 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.